Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8624010 | 0.86 | — | — | |
| SCHEMBL21315253 | 0.85 | — | — | |
| SCHEMBL23499284 | 0.83 | — | — | |
| SCHEMBL16877593 | 0.80 | TTR (0.38) | CYP11B1CYP11B2 | |
| SCHEMBL564628 | 0.80 | — | — | |
| SCHEMBL16878424 | 0.80 | TTR (0.33) | CYP11B1CYP11B2 | |
| SCHEMBL9147095 | 0.76 | — | — | |
| SCHEMBL22121608 | 0.76 | — | — | |
| SCHEMBL5641872 | 0.75 | — | — | |
| SCHEMBL16877662 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2373649-B1 | INDOLE AND BENZOXAZINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | JANSSEN PHARMACEUTICALS INC (US) | 2013-01-23 | — | — | EP | claimed |
| US-20120035167-A1 | INDOLE AND BENZOXAZINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Janssen Pharmaceuticals, Inc. | 2012-02-09 | — | — | US | claimed |
| EP-2373649-A1 | INDOLE AND BENZOXAZINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Ortho-McNeil-Janssen Pharmaceuticals, Inc. (US) | 2011-10-12 | — | — | EP | claimed |
| WO-2010060589-A1 | INDOLE AND BENZOXAZINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2010-06-03 | — | — | WO | claimed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| US-11725008-B2 | Ethanediamine-heterocycle derivatives as inhibitors of protein arginine methyltransferases | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-08-15 | — | — | US | disclosed |
| US-20230027126-A1 | ETHANEDIAMINE-HETEROCYCLE DERIVATIVES AS INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2023-01-26 | — | — | US | disclosed |
| US-11028083-B2 | Ethanediamine-heterocycle derivatives as inhibitors of protein arginine methyltransferases | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-06-08 | — | — | US | disclosed |
| EP-3758698-A1 | ETHANEDIAMINE-HETEROCYCLE DERIVATIVES AS INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASES | Board of Regents, The University of Texas System (US) | 2021-01-06 | — | — | EP | disclosed |
| US-20190270739-A1 | ETHANEDIAMINE-HETEROCYCLE DERIVATIVES AS INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASES | UNITED STATES GOVERNMENT | 2019-09-05 | — | — | US | disclosed |
| EP-2373649-B1 | INDOLE AND BENZOXAZINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | JANSSEN PHARMACEUTICALS INC (US) | 2013-01-23 | — | — | EP | disclosed |
| US-20120035167-A1 | INDOLE AND BENZOXAZINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Janssen Pharmaceuticals, Inc. | 2012-02-09 | — | — | US | disclosed |
| EP-2373649-A1 | INDOLE AND BENZOXAZINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Ortho-McNeil-Janssen Pharmaceuticals, Inc. (US) | 2011-10-12 | — | — | EP | disclosed |
| WO-2010060589-A1 | INDOLE AND BENZOXAZINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2010-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190270739-A1 | ETHANEDIAMINE-HETEROCYCLE DERIVATIVES AS INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASES | PRMT1, PRMT5, PRMT3 | CYP11B1 2266/4885CYP11B2 2555/4885 |
| US-11725008-B2 | Ethanediamine-heterocycle derivatives as inhibitors of protein arginine methyltransferases | PRMT1, PRMT5, PRMT3 | CYP11B1 2266/4885CYP11B2 2555/4885 |
| US-20120035167-A1 | INDOLE AND BENZOXAZINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | GRM2, GRM5, GRIA2 | CYP11B1 2168/4885CYP11B2 1188/4885 |
| US-11028083-B2 | Ethanediamine-heterocycle derivatives as inhibitors of protein arginine methyltransferases | PRMT1, PRMT5, PRMT3 | CYP11B1 2266/4885CYP11B2 2555/4885 |
| US-20230027126-A1 | ETHANEDIAMINE-HETEROCYCLE DERIVATIVES AS INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASES | PRMT1, PRMT5, PRMT3 | CYP11B1 2266/4885CYP11B2 2555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.